Investigating how certain drugs can block the effects of the androgen receptor in advanced prostate cancer.
Mechanisms of Androgen Receptor Inverse Agonists in Advanced Prostate Cancer
This study is looking at how certain new medications can help treat advanced prostate cancer, especially when other treatments aren't working anymore, to find better ways to slow down tumor growth and improve care for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10939509 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms by which androgen receptor inverse agonists can be used to treat advanced prostate cancer, particularly in cases where the cancer has become resistant to standard therapies. The study employs advanced molecular and computational biology techniques to explore how these drugs can alter the behavior of the androgen receptor and its associated gene expression. By using patient-derived xenograft models and cell lines that closely mimic the disease, the research aims to identify new therapeutic strategies that can effectively suppress tumor growth. Patients may benefit from insights gained into how to better target their cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adult males diagnosed with advanced prostate cancer, especially those who have developed resistance to androgen-deprivation therapy.
Not a fit: Patients with early-stage prostate cancer or those who do not have androgen receptor involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for advanced prostate cancer, particularly for patients who have not responded to existing therapies.
How similar studies have performed: Previous research has shown promise in targeting androgen receptors in prostate cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Gryder, Berkley E — Case Western Reserve University
- Study coordinator: Gryder, Berkley E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.